-
Mashup Score: 4
Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC - 12 day(s) ago
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
After 1 year of treatment, durvalumab + BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in DFS vs BCG therapy alone in BCG-naïve, high-risk NMIBC who had undergone prior TURBT. #blcsm https://t.co/CmLOelrxVx https://t.co/JCiv4ugYWG
-
-
Mashup Score: 4
A new type of robotic posterior surgery has been shown to be a treatment option for patients with devastated bladder outlets.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
A single-port robot was used to intraabdominally dissect the bladder neck and remove any necrotic issue or infected bone. #blcsm | @AmerUrological @lee_c_zhao https://t.co/KJTf0fdbXU
-
-
Mashup Score: 5
Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management @PGrivasMDPhD @fredhutch #blcsm https://t.co/meL8r1lUHT
-
-
Mashup Score: 2
The sBLA for NAI was submitted to the FDA in March 2025.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The @US_FDA has issued a refusal to file letter on an sBLA for nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC in the papillary indication. #blcsm https://t.co/oNQhSlPJRe
-
-
Mashup Score: 1Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC - 1 month(s) ago
Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Nadofaragene firadenovec-vncg elicited a strong CR rate in a small cohort of patients with high-risk BCG–unresponsive NMIBC with carcinoma in situ with or without papillary tumors. #blcsm https://t.co/KbjsQHy5ox
-
-
Mashup Score: 0
In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
A sBLA was submitted to the FDA for nogapendekin alfa inbakicept-pmln in combination with Bacillus Calmette-Guérin in patients with BCG-unresponsive non-muscle invasive bladder cancer. #blcsm https://t.co/fvu4vXNlDu
-
-
Mashup Score: 5
“There really wasn’t a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Joshua Meeks, MD, PhD, (@JoshMeeks) describes implications of the FDA's recent approval of perioperative durvalumab with chemotherapy for MIBC. @NM_Urology #blcsm https://t.co/RnihCav2VH
-
-
Mashup Score: 5
“There really wasn’t a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Joshua Meeks, MD, PhD, (@JoshMeeks) describes implications of the FDA's recent approval of perioperative durvalumab with chemotherapy for MIBC. @NM_Urology #blcsm https://t.co/RnihCav2VH
-
-
Mashup Score: 3FDA approval sought for Anktiva for papillary NMIBC - 1 month(s) ago
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
A sBLA has been submitted to the FDA for use of Anktiva plus BCG in BCG-unresponsive NMIBC in the papillary indication. #blcsm @DrPatSoonShiong https://t.co/ChZdlvl6F0
-
Statistically significant and clinically meaningful PFS and OS benefits were seen with disitamab vedotin + toripalimab vs standard chemo when used as a first-line treatment for patients with HER2+ locally advanced/metastatic urothelial carcinoma. #blcsm https://t.co/Ioo53azwc5